Skip to main
INSP
INSP logo

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 38%
Buy 33%
Hold 25%
Sell 4%
Strong Sell 0%

Bulls say

Inspire Medical Systems Inc. has demonstrated substantial growth in its operations, with Q4 revenue reaching $239.7 million, representing a 24.5% year-over-year increase, and earnings per share of $1.15 surpassing consensus estimates. The company has also seen a steady rise in the utilization of its Inspire therapy, which increased from 1.1 procedures per month in 2021 to 1.8 in 2024, indicating growing demand and effectiveness of its solutions for obstructive sleep apnea. The anticipated expansion of implanting centers, along with innovations such as the upcoming Gen 5 device and new treatment options, positions Inspire Medical Systems for continued revenue growth and market penetration.

Bears say

Inspire Medical Systems faces a negative outlook primarily due to potential challenges in market penetration and utilization of its implant centers, which could delay its path to profitability and allow new entrants to capture market share. Revenue estimates for 2025 remain stagnant and modestly below management guidance, indicating a lack of growth momentum, while expectations for earnings per share have also been revised downwards, suggesting some caution regarding future performance. Additionally, there are concerns that advertising expenditure, although decreasing as a percentage of revenue, may not generate sufficient returns to support increased sales in a competitive landscape.

INSP has been analyzed by 24 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 33% recommend Buy, 25% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 24 analysts, INSP has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $186.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $186.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.